

# Modulation of In Vitro Monocyte Cytokine Responses to *Leishmania donovani*

## Interferon- $\gamma$ Prevents Parasite-induced Inhibition of Interleukin 1 Production and Primes Monocytes to Respond to *Leishmania* by Producing Both Tumor Necrosis Factor- $\alpha$ and Interleukin 1

Neil E. Reiner,<sup>\*,†</sup> Winnie Ng,<sup>\*</sup> Christopher B. Wilson,<sup>§</sup> W. Robert McMaster,<sup>||</sup> and Sandra K. Burchett<sup>§</sup>

Division of Infectious Diseases, Departments of <sup>\*</sup>Medicine, and Departments of <sup>†</sup>Microbiology and <sup>||</sup>Medical Genetics, University of British Columbia School of Medicine and Vancouver General Hospital, Vancouver British Columbia, Canada V5Z-1M9; and Division of Infectious Diseases, <sup>§</sup>Department of Pediatrics, University of Washington and Children's Hospital and Medical Center, Seattle, Washington 98105

### Abstract

Cytokines produced by mononuclear cells are important regulatory and effector molecules and evidence has been presented to support a role at least for tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interferon- $\gamma$  (IFN- $\gamma$ ) in host defense against *Leishmania*. In the present study, we examined the production of TNF- $\alpha$  and interleukin 1 (IL-1) by resting and IFN- $\gamma$ -primed peripheral blood monocytes infected in vitro with *Leishmania donovani*. Monocytes produced neither IL-1 nor TNF- $\alpha$  during challenge with *Leishmania*. Cells preinfected with *Leishmania* synthesized normal amounts of TNF- $\alpha$ , but had diminished production of IL-1 in response to stimulation with either *S. aureus* or lipopolysaccharide (LPS). The induction by *S. aureus* or LPS of IL-1 $\beta$  mRNA accumulation in infected cells was normal despite diminished intracellular or supernatant IL-1 protein and bioactivity. Thus, inhibition of IL-1 production by *Leishmania* most probably reflected diminished translation of IL-1 $\beta$  mRNA. Pretreatment of cells with IFN- $\gamma$  abrogated infection-induced inhibition of IL-1 production and primed cells for the production of both IL-1 and TNF- $\alpha$  upon subsequent exposure to *Leishmania*. These results indicate that *L. donovani* has evolved the capacity to infect mononuclear phagocytes, without stimulating the production of two potentially host-protective monokines. The ability of IFN- $\gamma$  to prime monocytes to produce TNF- $\alpha$  and IL-1 in response to infection with *Leishmania* and to prevent inhibition of IL-1 production may have implications for immunotherapy with this lymphokine. (*J. Clin. Invest.* 1990. 85:1914-1924.) *Leishmania* • monocytes • monokines • interferon- $\gamma$

### Introduction

Cells of the mononuclear phagocyte series perform a large array of functions that are crucial to the integrity of the immune system and for host defense (1-3). In addition to strictly cellular functions such as antigen processing and presentation, antibody-dependent and antibody-independent cellular cytotoxicity and killing of both intracellular and extracellular mi-

croorganisms, mononuclear phagocytes also produce and secrete a variety of cytokines that have potent, pleiotropic effects within the host (2). Important examples of the latter are interleukin 1 (IL-1) and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ),<sup>1</sup> two cytokines which mediate a large and frequently overlapping repertoire of biological activities (4-8). In particular, IL-1 and TNF- $\alpha$  have been shown to be important elements in the host response to microbial invasion. For example, both IL-1 and TNF- $\alpha$  are produced in response to a variety of microbes and microbial products (4, 6) and in turn these cytokines have been shown to mediate antimicrobial activities both in vitro and in vivo (9-12).

Paradoxically, in spite of the prominent role of mononuclear phagocytes in host defense, a large number of diverse microorganisms have evolved the capacity to establish a state of intracellular parasitism within these cells. This suggests the possibility that in order to insure their own survival, these organisms may use strategies designed to either evade or subvert the regulatory or effector functions of their target cells. Protozoa of the genus *Leishmania* are an example of a group of organisms that have adapted remarkably well in respect to their ability to infect, propagate and persist within mononuclear phagocytes (13, 14). Given the pivotal roles of mononuclear phagocytes and of their cytokine products in mammalian homeostasis, it is important to understand how these functions may be perturbed during chronic intracellular infection. Moreover, with respect to *Leishmania* in particular, understanding how cytokine production is modulated in infected mononuclear phagocytes may be of fundamental importance to the immunobiology of the leishmaniasis. Support for this concept derives from recent findings that demonstrated a protective role for TNF- $\alpha$  in experimental leishmaniasis (15) and from studies in which interferon- $\gamma$  (IFN- $\gamma$ ), a lymphokine that potentiates monocyte cytokine production (16-19), was shown to have therapeutic efficacy in human visceral leishmaniasis (20). Based upon these considerations, in the present study the modulation of IL-1 and TNF- $\alpha$  production by human monocytes during infection with *Leishmania donovani* (the causative agent of visceral leishmaniasis in the Old World) was examined. The question of whether IFN- $\gamma$  could modulate human monocyte responses to *L. donovani* for the production of TNF- $\alpha$  and IL-1 was also studied.

### Methods

*Leishmania* and *leishmania* lysate. Amastigotes of the Sudan strain 2S of *L. donovani* used in this study were isolated from spleens of male

Address reprint requests to Dr. Reiner, Department of Medicine, University of British Columbia, 910 West, 10th Avenue, Vancouver, BC V5Z 1M9, Canada.

Received for publication 1 August 1988 and in revised form 9 February 1990.

*J. Clin. Invest.*

© The American Society for Clinical Investigation, Inc.

0021-9738/90/06/1914/11 \$2.00

Volume 85, June 1990, 1914-1924

1. Abbreviations used in this paper: TNF, tumor necrosis factor.

Syrian hamsters as described in detail previously (21). For use in some experiments, a soluble parasite lysate was prepared by suspending amastigotes in calcium- and magnesium-free Hanks' balanced salt solution and subjecting the suspension to six freeze ( $-70^{\circ}\text{C}$ )/thaw cycles. The suspension was then centrifuged at  $12,500\text{ g}$  for 20 min, and the supernatant was recovered, filter-sterilized, and adjusted to  $1\text{ mg/ml}$  after protein determination by protein assay (Bio-Rad Laboratories, Richmond, CA).

**Reagents and chemicals.** RPMI 1640 and Dulbecco's modified Eagle's medium (DME,  $4,500\text{ mg/liter}$  glucose) were prepared in the media preparation facility at the Terry Fox Laboratory of the Cancer Control Agency of British Columbia, and were supplemented with L-glutamine ( $2\text{ mM}$ ), 2-mercaptoethanol ( $5 \times 10^{-5}\text{ M}$ ), penicillin ( $100\text{ U/ml}$ ), and streptomycin ( $100\text{ }\mu\text{g/ml}$ ). In addition, DME was also supplemented with sodium pyruvate ( $0.01\text{ mM}$ ), Hepes ( $10\text{ mM}$ ), L-arginine-HCl ( $1.48\text{ mM}$ ), folic acid ( $0.01\text{ mM}$ ), and asparagine ( $0.27\text{ mM}$ ). Hanks' balanced salt solution (HBSS), also prepared at the Terry Fox Laboratory, was supplemented with penicillin and streptomycin and Hepes ( $10\text{ mM}$ ) and adjusted to pH 7.4 with  $7.5\%$  sodium bicarbonate. Histopaque (no. 1077) and lipopolysaccharide (LPS) (L-3129, *Escherichia coli* 0127:B8, lot no. 3123-25, B2F-4012) were from Sigma Chemical Co., St. Louis, MO. Fixed *S. aureus* cells of the Cowan I strain were from Calbiochem-Behring Corp., La Jolla, CA, as Pansorbin (no. 507858) as a  $10\%$  (wt/vol) solution in PBS. Methyl-tritiated thymidine was from Amersham, Oakville, Ontario with sp act  $5\text{ Ci/mmole}$ . Recombinant human IFN- $\gamma$  (lot no. K9079A, sp act  $2.7 \times 10^7\text{ U/mg}$ ), recombinant human TNF- $\alpha$  (sp act  $5 \times 10^7\text{ U/mg}$ ), and the cDNA probes for human IL-1 $\beta$  (22) and human TNF- $\alpha$  (23) were generous gifts from Genentech Inc., South San Francisco, CA.

**Cell preparation and culture.** Peripheral blood mononuclear cells were isolated from buffy coats (obtained from normal human volunteers by the British Columbia and Yukon Division of the Canadian Red Cross) by centrifugation ( $800\text{ g}$  for 15 min) over Histopaque. After three washes in HBSS, the cells were resuspended in RPMI 1640 with  $10\%$  human serum at  $1 \times 10^7$  viable cells per ml and dispensed into  $150\text{-cm}^2$  tissue culture flasks ( $20\text{ ml}$  per flask for the preparation of cellular RNA) and incubated at  $37^{\circ}\text{C}$  in a  $5\% \text{ CO}_2/95\%$  air, humidified atmosphere for 45 min. Nonadherent cells were removed by vigorous washing with divalent cation-free HBSS ( $37^{\circ}\text{C}$ ) and the flasks were replenished with RPMI 1640 supplemented with  $20\%$  fresh human serum for culture with or without the addition of various stimuli. Adherent monolayers prepared in this manner were  $89 \pm 5\%$  monocytes by morphologic and phagocytic criteria as determined by microscopic examination of Diff-Quik (B4132-1, CanLab, Vancouver, BC) stained preparations.

Monocyte supernatants for IL-1 and for TNF- $\alpha$  assays were generated by culturing  $1 \times 10^6$  peripheral blood mononuclear cells per chamber of eight-chamber Lab-Tek chamber slides (no. 4808, Miles Scientific, Inc., Naperville, IL) in DME/ $10\%$  heat-inactivated fetal bovine serum (FBS) (lot 1111646, Hyclone Laboratories, Logan, Utah) for 60 min at  $37^{\circ}\text{C}$  in  $5\% \text{ CO}_2/95\%$  air. Nonadherent cells were removed by washing as above for flasks, and the chambers were replenished with DME  $10\%$  FBS with or without stimulants. After overnight incubation ( $12\text{--}16\text{ h}$ ), cell-free supernatants were collected and either assayed immediately or stored at  $-70^{\circ}\text{C}$ . Monolayers prepared in this manner were  $86 \pm 5\%$  monocytes by both morphologic and phagocytic criteria as described above for flask cultures.

**IL-1 assay.** IL-1 activity in monocyte supernatants was assayed by the induction of [ $^3\text{H}$ ]thymidine incorporation into D10.G4.1 cells in the presence of a suboptimal concentration of concanavalin A ( $0.625\text{ }\mu\text{g/ml}$ , no. 234567, Calbiochem-Behring Corp.), (24). One unit of IL-1 activity was defined as that which stimulated  $50\%$  of maximal [ $^3\text{H}$ ]thymidine incorporation by D10.G4.1 cells. Results from individual experiments were normalized against a standard preparation of IL-1 produced from normal human monocytes stimulated with *S. aureus* as described (25). As used under the experimental conditions of this study, the D10.G4.1 assay was shown to be specific for IL-1. This was demonstrated by neutralization of monocyte supernatants by rabbit

polyclonal antisera specific for IL-1 $\alpha$  or IL-1 $\beta$  generously provided by Dr. Kenneth H. Grabstein of Immunex Corporation, Seattle, WA. Under the experimental conditions of this study,  $>95\%$  of the IL-1 activity detected in monocyte supernatants was neutralized by treatment with the anti-IL-1 $\beta$  serum. In selected experiments, the content of immunoreactive IL-1 $\beta$  in monocyte supernatants was determined by ELISA using an immunoassay kit (03-0096, Cistron Biotechnology, Pinebrook, NJ). The sensitivity of this assay system is  $20\text{ pg/ml}$  and there is no cross-reactivity with IL-1 $\alpha$  or TNF.

**Assay for TNF- $\alpha$ .** Immunoreactive TNF- $\alpha$  was measured by ELISA using a rabbit antibody to recombinant human TNF- $\alpha$  as the capture antibody and horseradish peroxidase conjugated mouse monoclonal anti-recombinant human TNF- $\alpha$  as the second antibody. Both antibodies were generously supplied by Genentech, Inc. The standard curve for detection of recombinant TNF- $\alpha$  was linear in the range of  $25\text{--}1,000\text{ pg/ml}$ .


**Northern blot analyses.** Total RNA was isolated from cells as described by Chirgwin et al. (26) using cesium chloride gradients. RNA was denatured and size separated on agarose formaldehyde gels as described (27) and transferred to nylon membranes (Hybond-N, Amersham). Blots were prehybridized, hybridized and washed following the manufacturer's protocol. IL-1 $\beta$  and TNF- $\alpha$  mRNAs were detected using human cDNA probes generously provided respectively by Dr. Patrick Gray (22) and Dr. Dianne Pennica (23) of Genentech Inc. DNA was oligolabeled with [ $^3\text{P}$ ]dCTP using random primers as described (28).

**Statistical analysis.** Except where otherwise stated, the results shown are representative data from a minimum of three similar or identical experiments which yielded comparable results. Unless otherwise indicated, differences between experimental groups were examined using Student's *t* test for independent means.

## Results

**Human monocyte IL-1 production during infection with Leishmania.** Supernatants of freshly isolated, normal peripheral blood monocytes infected with *L. donovani* for  $\sim 12\text{ h}$  showed no increase in IL-1 content when compared to control unstimulated cells (Fig. 1). In contrast, cells stimulated with heat-inactivated *S. aureus* or with LPS, released large amounts of IL-1 activity into their supernatants. The absence of increased IL-1 activity in the supernatants of leishmania-infected cultures appeared to be related to the failure of monocytes to accumulate IL-1 mRNA in response to infection (Fig. 2). Northern analysis showed that cells stimulated with *S. aureus* or with LPS for  $\sim 12\text{ h}$  accumulated readily detectable amounts of IL-1 $\beta$  mRNA, whereas *Leishmania*-infected cells, like unstimulated cells, did not.


**Inhibition of monocyte IL-1 production by leishmania infection.** To examine whether monocytes infected with *L. donovani* could respond to a second stimulus for the production of IL-1, cells were infected with *Leishmania* for  $4\text{ h}$  and then secondarily stimulated with either *S. aureus* or with LPS. Supernatants were collected  $\sim 12\text{ h}$  after the addition of secondary stimuli and were assayed for IL-1 activity. The results shown in Fig. 1 demonstrate that supernatants of cells preinfected with *Leishmania* and secondarily stimulated with either *S. aureus* or with LPS contained significantly reduced IL-1 content when compared to supernatants of noninfected cells. This result was not likely to be related to suppressive factors in monocyte-conditioned media since, as shown in Table I, exactly parallel results were obtained when supernatants (derived from cells identically treated in separate experiments) were assayed for immunoreactive IL-1 $\beta$  by ELISA.



**Figure 1.** Human monocytes preinfected with *L. donovani* have suppressed IL-1 responses to *S. aureus* and LPS. Monolayers of freshly isolated human monocytes (> 90% pure by morphologic and phagocytic criteria) were either untreated or exposed to amastigotes of *Leishmania* at a parasite/cell ratio of 10:1 (ultimate infection rate was 77% with 7 amastigotes per cell). 4 h later the monolayers were challenged with *S. aureus* (0.005% as Pansorbin fixed *S. aureus*), LPS (1  $\mu$ g/ml) or nil. Approximately 16 h later cell-free supernatants were harvested and assayed for IL-1 activity using D10.G4.1 cells. The results shown are from one of three identical experiments which yielded similar results, and represent the mean  $\pm$  SD of triplicate determinations for each experimental group. The differences between *S. aureus* vs. *Leishmania*-*S. aureus* and LPS vs. *Leishmania*-LPS were significant at the 2% and 2.5% levels, respectively.

Reduced IL-1 content of supernatants derived from cells preinfected with *Leishmania* and secondarily stimulated with either *S. aureus* or with LPS was not related to altered kinetics of IL-1 release. Thus, as shown in Fig. 3, irrespective of the duration of incubation of *Leishmania*-infected cells with LPS, in comparison to LPS treated control cells, supernatants of infected monocytes had decreased IL-1 activity. In addition, reduced IL-1 content of supernatants derived from infected cells was shown (Table II) not to be related to intracellular accumulation of cytokine.

Additional experiments were carried out to determine whether inhibition of IL-1 production by *Leishmania* required infection with intact organisms. To examine this question, 4 h before stimulation with *S. aureus*, cells were either infected with *Leishmania* or treated with a soluble parasite lysate (prepared as described in Methods). As shown in Table III, cells preinfected with *Leishmania* had significantly decreased responses to *S. aureus* for IL-1 production. In contrast, in two of three experiments, pretreatment of cells with the parasite lysate (10  $\mu$ g/ml) did not significantly affect the IL-1 response to



**Figure 2.** Northern blot analysis of IL-1  $\beta$  mRNA in human monocytes. Monolayers of freshly isolated monocytes treated as indicated below for  $\sim$  16 h were washed and lysed in guanidium isothiocyanate. Total cytoplasmic RNA, 5  $\mu$ g, was fractionated on a 1.2% agarose formaldehyde gel and transferred to Hybond-N and hybridized with <sup>32</sup>P-labeled cDNA insert of pHu IL-1 $\beta$  (right). Lane 1, unstimulated monocytes; lane 2, *Leishmania*-infected monocytes; lane 3, monocytes stimulated with *S. aureus*; lane 4, monocytes treated with LPS (1  $\mu$ g/ml). (Left) Gel stained with acridine orange.

**Table I.** Content of Immunoreactive IL-1 $\beta$  in Supernatants of Monocytes Infected with *L. donovani* and Secondarily Treated with Either *S. aureus* or LPS

Cell treatment	Immunoreactive IL-1 $\beta$ Experiment No.	
	1	2
	ng/ml	
Nil	<40*	<40
<i>S. aureus</i>	7,920	6,016
<i>Leishmania</i> and <i>S. aureus</i>	2,144	1,424
LPS	17,504	25,696
<i>Leishmania</i> and LPS	6,240	8,960

Monolayers of human monocytes were prepared and treated as described in the legend to Fig. 1. Cells treated with *Leishmania* were  $\sim$  70–80% infected with an average of three amastigotes per cell. 16 h after the addition of stimuli, cell-free supernatants were collected and assayed for IL-1 $\beta$  by ELISA.

\* Average of duplicate measurements for each treatment group.

# Cell Treatment




Figure 3. Kinetics of IL-1 release into supernatants of monocytes preinfected with *Leishmania*. Cells were prepared and treated as described in the legend to Fig. 1. After the indicated duration of exposure to LPS (1 µg/ml) supernatants were collected and assayed for IL-1 content using the D10.G4.1 cells. The results shown are from one of two identical experiments which yielded similar results, and represent the mean±SD of triplicate determinations for each experimental group. The differences between LPS vs. *Leishmania*-LPS at all time points were significant at ≤ the 5% level.

Table II. Supernatant and Intracellular IL-1 Bioactivities Derived from Monocytes Infected with *L. donovani* and Secondly Treated with Either *S. aureus* or LPS

Cell treatment	IL-1 bioactivity Experiment No.	
	1	2
	Supernatant/intracellular	Supernatant/intracellular
	U/ml	
Nil	23±15/3±2*	22±19/165±62
<i>Leishmania</i>	19±15/6±5	nil/199±109
<i>S. aureus</i>	1524±317/104±17‡	3355±1138/73±90‡
<i>Leishmania</i> and <i>S. aureus</i>	175±97/122±30	37±27/122±876
LPS	740±138/165±8‡	2944±1318/130±74‡
<i>Leishmania</i> and LPS	247±135/156±38	110±93/30±5.2

Monolayers of human monocytes were prepared as described in the legend to Fig. 1 using 96-well, flat-bottom tissue culture plates and were either untreated or infected with *L. donovani* at a parasite/cell ratio of 10:1. 4 h later cells were either untreated or treated with LPS of *S. aureus*. 16 h after the addition of stimuli, cell-free supernatants and cell lysates were collected as described previously (25) from all treatment groups and assayed for IL-1 activity using D10.G4.1 cells. \* Mean±SD of triplicate determinations for each experimental group. ‡ The differences in IL-1 activities in supernatants of cells treated with *S. aureus* vs. *Leishmania*-*S. aureus* and LPS vs. *Leishmania*-LPS were significant at ≤ the 2.5% level.

*S. aureus*. In fact, in one experiment pretreatment with the lysate actually augmented the IL-1 response to *S. aureus*. These findings indicated that inhibition of IL-1 production by *Leishmania* required infection with intact organisms.

To analyse further, the mechanism(s) of inhibition of IL-1 production by *Leishmania*, cells were treated exactly as described in Fig. 1, and after 11–12 h of incubation with secondary stimuli, total RNA was isolated and hybridized with a cDNA probe for IL-1β. As shown in Fig. 4, in these experiments cells treated with *S. aureus* (lane 3) or with LPS (lane 2) alone accumulated significant amounts of IL-1β mRNA. Of interest, monocytes preinfected with *Leishmania* and secondarily stimulated with LPS accumulated a level of IL-1β mRNA equal to that detected in cells stimulated with LPS alone (compare lanes 2 and 4), even though there was a significant reduction in the amount of IL-1 detected in the corresponding supernatants. In contrast, in the experiment shown here, monocytes preinfected with *L. donovani* and secondarily stimulated with *S. aureus* (lane 5) had no detectable IL-1β mRNA. A result identical to this was also obtained in a second experiment involving cells from another donor (data not shown). Inhibition of *S. aureus*-induced IL-1β mRNA accumulation in *Leishmania*-infected cells was not, however, a constant finding. Thus, in four additional experiments involving cells from separate donors (one of which is shown in Fig. 5 A) monocytes preinfected with *L. donovani* and secondarily stimulated with *S. aureus* had a level of IL-1β mRNA equal to that detected in cells stimulated with *S. aureus* alone. Again, this result was found despite a significant reduction in

Table III. Comparative Effects of Infection with *Leishmania* or Treatment with a Soluble Parasite Lysate on Monocyte IL-1 Production

Cell treatment	IL-1 bioactivity Experiment No.		
	1	2	3
	U/ml		
Nil	ND*	ND	ND
<i>Leishmania</i>	ND	ND	ND
Lysate	ND	ND	ND
<i>S. aureus</i>	8,690±1,487 <sup>‡</sup>	5,225±1,468	1,134±120
<i>Leishmania</i> and <i>S. aureus</i>	3,511±836 <sup>§</sup>	641±525 <sup>§</sup>	535±76 <sup>§</sup>
Lysate and <i>S. aureus</i>	13,692±4972	2,830±666	2,006±357 <sup>  </sup>

Monolayers of human monocytes were prepared as described in the legend to Fig. 1 using Lab-Tek chamber slides. Cells were either untreated, infected with *L. donovani* at a parasite/cell ratio of 10:1 or treated with a soluble parasite lysate (10 µg/ml) prepared as described in Methods. After 4 h of preincubation under these conditions, cells were either untreated or treated with *S. aureus* and 16 h later cell-free supernatants were collected and assayed for IL-1 activity using D10.G4.1 cells.

\* ND, not detectable.

<sup>‡</sup> Mean±SD of triplicate determinations for each experimental group.

<sup>§</sup> The differences in IL-1 activities in supernatants of cells treated with *Leishmania*-*S. aureus* vs. *S. aureus* alone were significant at ≤ the 1% level.

<sup>||</sup> The difference in IL-1 activities in supernatants of cells treated with lysate and *S. aureus* vs. *S. aureus* alone was significant at the 2% level.




Figure 4. Northern blot analysis of IL-1 $\beta$  mRNA in human monocytes. Monocyte monolayers treated as indicated below were lysed in guanidium isothiocyanate ~ 12 h after addition of *S. aureus* or LPS. RNA was isolated and analyzed for IL-1 $\beta$  mRNA (right) as described in the legend to Fig. 2. Lane 1, unstimulated cells; lane 2, LPS (1 µg/ml) stimulated cells; lane 3, *S. aureus*-treated cells; lanes 4 and 5, cells infected with *Leishmania* for 4 h before being stimulated with either LPS (lane 4) or *S. aureus* (lane 5). (Left) Gel stained with acridine orange.




Figure 5. Northern blot analysis of IL-1 $\beta$  and TNF- $\alpha$  mRNA in human monocytes. Monocyte monolayers treated as indicated below were lysed in guanidium isothiocyanate ~ 12 h after the addition of *S. aureus*. RNA was isolated and analyzed as described in the legend to Fig. 2. (A) IL-1 $\beta$  cDNA probe; (B) TNF- $\alpha$  cDNA probe; (C) ethidium bromide stained gel. Lane 1, unstimulated monocytes; lane 2, *Leishmania*-infected monocytes; lane 3, monocytes stimulated with *S. aureus*; lane 4, cells infected with *Leishmania* for 4 h before stimulation with *S. aureus*.

the amount of IL-1 activity detected in the corresponding supernatants. The explanation for the variable effect of *Leishmania* on IL-1 $\beta$  mRNA levels in these experiments involving secondary stimulation with *S. aureus* is not clear, but may be related to individual donor variability. Nevertheless, taken together the results of these experiments indicated that (a) inhibition of IL-1 production in response to either *S. aureus* or LPS was a constant finding in *Leishmania*-infected cells, (b) in the case of LPS, decreased IL-1 bioactivity and immunoreactive protein in monocyte supernatants was regularly associated with the normal accumulation of IL-1 $\beta$  mRNA in infected monocytes, and (c) with respect to *S. aureus* the predominant mechanism of inhibition of IL-1 synthesis in *Leishmania*-infected cells was also postmessage accumulation, but was variably associated with decreased IL-1 $\beta$  mRNA levels as well. Thus, inhibition by *Leishmania* of the IL-1 response to either *S. aureus* or LPS was likely related predominantly to mechanisms affecting translation of IL-1 $\beta$  mRNA or possibly to stability of translated protein.

**Monocyte TNF- $\alpha$  production during infection with *L. donovani*.** Infection of freshly isolated human monocytes with *Leishmania* did not result in the induction of TNF- $\alpha$  production. As shown in Figure 6, supernatants of cells infected with *L. donovani* for ~ 16 h had no detectable increase in immunoreactive TNF- $\alpha$  content when compared with control cells. In contrast, stimulation of monocytes with either *S. aureus* or with LPS was associated with significant increases in TNF- $\alpha$  content. Monocyte supernatants were also assayed for TNF- $\alpha$  bioactivity in the L929 cytotoxicity assay. The results (data not shown) indicated that TNF- $\alpha$  bioactivity in monocyte supernatants paralleled exactly the levels of immunoreactive cytokine shown in Fig. 6.

In contrast to the findings with IL-1, monocytes preinfected with *Leishmania* responded normally to secondary stimuli for the production of TNF- $\alpha$ . As shown in Fig. 6, supernatants of cells infected for 4 h before exposure to either *S. aureus* or LPS had levels of immunoreactive cytokine that were equivalent to those found in supernatants of cells treated




Figure 6. Human monocytes infected with *L. donovani* have normal TNF- $\alpha$  responses to *S. aureus* or LPS. Monolayers were prepared and treated, and supernatants were harvested exactly as described in the legend to Fig. 1. Immunoreactive TNF- $\alpha$  was measured by ELISA. The results shown represent the means $\pm$ SD of values obtained from four identical experiments performed using cells from different donors. ND, not detectable.

with either *S. aureus* or LPS alone. These results were also confirmed by measurements of TNF- $\alpha$  bioactivity in monocyte supernatants (data not shown). Consistent with these observations, was the finding that the steady-state level of TNF- $\alpha$  mRNA in *Leishmania*-infected, *S. aureus*-treated cells was equivalent to the level of TNF- $\alpha$  mRNA detected in *S. aureus*-induced normal monocytes (Fig. 5 B).

**Modulation by IFN- $\gamma$  of *L. donovani* effects on monocyte IL-1 production.** The results of the experiments reported above, indicated that *L. donovani* was capable of infecting

human monocytes without eliciting the production of either IL-1 or TNF- $\alpha$ . Furthermore, *Leishmania* infection selectively inhibited monocyte responses to secondary stimuli for cytokine production. Thus, preinfection with *Leishmania* inhibited monocyte responses to *S. aureus* and to LPS for the production of IL-1, but not for the synthesis of TNF- $\alpha$ . Because IFN- $\gamma$  had been shown to upregulate IL-1 synthesis under certain conditions, we asked whether treatment with this cytokine could prevent parasite-induced inhibition of the IL-1 response to a secondary stimulus. As shown in Fig. 7, monocytes




Figure 7. Interferon- $\gamma$  treatment protects monocytes from inhibition of IL-1 production by *L. donovani*. Monolayers were prepared and treated, and supernatants were harvested and assayed as described in the legend to Fig. 1. Where indicated, cells were treated with IFN- $\gamma$  (200 U/ml) at the designated time points. The results shown are from one of three identical experiments which yielded similar results. The values represent the mean $\pm$ SD of triplicate determinations for each experimental group. The difference between *S. aureus* vs. *Leishmania*-*S. aureus* was significant at the 1% level. The IL-1 activity detected in the supernatants of cells treated with IFN- $\gamma$  at -4 h (followed by Ld at 0 h) was not different from the activity in supernatants of cells treated with *S. aureus* alone. The difference in IL-1 activities in supernatants of cells treated simultaneously with IFN- $\gamma$  and *Leishmania* in comparison to supernatants

of cells receiving *Leishmania* (only) followed by *S. aureus* was significant at the 0.1% level. Untreated cells, or cells treated with IFN- $\gamma$  alone had no detectable IL-1 activities in their supernatants.

preinfected with *Leishmania* for 4 h were markedly unresponsive to *S. aureus* for the production of IL-1. Treatment of cells with IFN- $\gamma$  for 4 h before infection, however, abrogated *Leishmania*-induced inhibition of the IL-1 response to *S. aureus* ( $n = 6$ ). The protective effect of IFN- $\gamma$  was found to be time dependent. Thus, as shown in Fig. 7, significant enhancement of the response to *S. aureus* (by *Leishmania*-infected cells) was also seen when IFN- $\gamma$  and *Leishmania* were added simultaneously. On the other hand, when added at progressively later time points (relative to infection) the protective effect of IFN- $\gamma$  was eventually lost.

To examine whether there were conditions under which monocytes would respond to *Leishmania* alone by producing IL-1, cells were primed with IFN- $\gamma$  before infection. The results shown in Fig. 8 indicate that pretreatment of freshly isolated monocytes with IFN- $\gamma$  could prime cells to respond to *Leishmania* with the synthesis of IL-1. Supernatants of cells incubated with IFN- $\gamma$  for 4 h before the addition of *Leishmania* (for an additional 16 h) demonstrated a significant increase in IL-1 content when compared to supernatants of control nonstimulated cells. Treatment of monocytes with IFN- $\gamma$  alone did not result in increased supernatant IL-1 activity in comparison to conditioned medium from unstimulated control cells.

The ability of cytokine treatment to prime cells to respond to *Leishmania* by producing IL-1 was also time-dependent. As shown in Fig. 8, the simultaneous addition of *Leishmania* and IFN- $\gamma$  resulted in significantly less priming for IL-1 production when compared to cytokine pretreatment. When leishmania infection was followed either 2 or 4 h later by the addition of IFN- $\gamma$ , the ability to convert cells from being IL-1 nonresponders to IL-1 responders was progressively lost. The priming effect of IFN- $\gamma$  for monocyte IL-1 synthesis in response to *Leishmania* was found to vary amongst monocyte

donors. Thus, significant priming was observed in six out of nine experiments using cells from distinct donors. This variability may be related to heterogeneous responses to IFN- $\gamma$ .

IFN- $\gamma$  primes monocytes to produce TNF- $\alpha$  in response to *L. donovani*. As shown in Table IV, monocytes primed with IFN- $\gamma$  produced large amounts of immunoreactive TNF- $\alpha$  in response to infection with *Leishmania* (priming was observed in three out of five separate experiments using cells from individual donors). Treatment of cells with either IFN- $\gamma$  or *Leishmania* alone resulted in minimal or negligible amounts of TNF- $\alpha$  production (when compared to unstimulated cells). On the other hand, the content of immunoreactive TNF- $\alpha$  detected in supernatants of cells (from three of five donors) primed with IFN- $\gamma$  for 4 h before the addition of *Leishmania* was increased significantly (from 7- to 30-fold) in comparison to supernatants of cells treated with *Leishmania* alone.

## Discussion

The results of the present study demonstrate that amastigotes of *L. donovani* are capable of infecting human monocytes without stimulating these cells to synthesize IL-1 or to secrete IL-1 activity into their supernatants. This finding is in agreement both with previous experiments from this laboratory which examined the interaction of this organism with murine macrophages (25) and with the data of Crawford et al. (29). The latter workers reported that human monocytes infected with *Leishmania major* also did not produce IL-1. On the other hand, these findings are in direct contrast to those recently reported by Cillari and co-workers demonstrating that murine macrophages responded to infection with *L. major* by producing IL-1 (30). The explanation for the divergent findings of these two studies that examined *L. major* is not known. The potential difference, however, between *L. donovani* and *L.*




Figure 8. Interferon- $\gamma$  treatment primes monocytes to respond to *L. donovani* with the production of IL-1. The details of cell preparation, infection with *Leishmania* and IL-1 assay were as described in the legend to Fig. 1. IFN- $\gamma$  was used at 200 U/ml. The results shown are from one of nine identical experiments, six of which yielded similar results, and represent the mean  $\pm$  SD of triplicate determinations for each group. The differences found when comparing IL-1 activities in supernatants of cells treated with *Leishmania* alone in comparison to supernatants of cells treated with *Leishmania* and with IFN- $\gamma$  at either -4 h, 0 h, or +2 h were all significant at the 2% level or less. Supernatants of cells treated with IFN- $\gamma$  alone had no detectable IL-1 bioactivity.



Table IV. IFN- $\gamma$  Primes Human Monocytes to Produce TNF- $\alpha$  in Response to *L. donovani*

Cell treatment	Immunoreactive TNF- $\alpha$ Experiment No.				
	1	2	3	4	5
	pg/ml				
Nil	<50	<50	<50	142	659
<i>L. donovani</i>	145	210	335	132	221
IFN- $\gamma$ *	36	670	<50	240	131
IFN- $\gamma$ + <i>L. donovani</i> †	2,070	6,400	2,500	147	526

Monolayers of human monocytes, prepared as described in the legend to Fig. 1, were either untreated or infected with *L. donovani* at a parasite/cell ratio of 10:1. Supernatants were removed after 16 h of culture and analyzed for immunoreactive TNF- $\alpha$  by ELISA. For the five experiments shown the infection rate was  $88.9 \pm 7.8\%$  (mean  $\pm$  SD) with a mean of  $8.1 \pm 2.9$  amastigotes per cell.

\* IFN- $\gamma$  was used at 200 U/ml.

† Monolayers treated with both IFN- $\gamma$  and *L. donovani* were incubated with lymphokine for 4 h before infection. The values for immunoreactive TNF- $\alpha$  in supernatants of cells treated with *L. donovani* alone and those detected in supernatants of cells treated with IFN- $\gamma$  + *L. donovani* were log transformed and compared by Student's paired *t* test (two-tailed). The mean increase in TNF- $\alpha$  content associated with IFN- $\gamma$  pretreatment was significant at  $P = 0.04$ .

major with respect to the production of IL-1 by infected mononuclear cells may be related to fundamental differences in the immunobiology of infection with these two species of *Leishmania*.

The data presented above furthermore establish that cellular unresponsiveness to *Leishmania donovani* with respect to IL-1 synthesis is related to the absence of IL-1 $\beta$  mRNA accumulation following monocyte infection (Fig. 2). This finding is consistent with and provides an explanation for our prior inability to detect either intracellular, membrane or secreted IL-1 activities associated with leishmania-infected murine macrophages (25).

The data presented herein also indicate that in addition to infecting human monocytes without inducing IL-1 production, *L. donovani* is capable of inhibiting monocyte IL-1 responses to other stimuli. Inhibition by *Leishmania* of the IL-1 response to either *S. aureus* or LPS was likely related predominantly to mechanisms affecting translation of IL-1 $\beta$  mRNA or possibly to stability of translated protein. This conclusion is supported by several findings including (a) normal steady-state levels of either *S. aureus* (Fig. 5) or LPS-induced (Fig. 4) IL-1 $\beta$  mRNA in *Leishmania*-preinfected cells, (b) decreased supernatant content of IL-1 was not explained by altered kinetics of IL-1 release induced by infection (Fig. 3), and (c) the absence of the intracellular accumulation of IL-1 in infected cells (Table II). Although the predominant mechanism of inhibition of *S. aureus*-induced IL-1 synthesis in *Leishmania*-infected cells was post-IL-1 $\beta$  message accumulation, these particular experimental conditions were variably associated with decreased steady-state IL-1 $\beta$  mRNA levels as well ( $n = 2$  out of 6 experiments). The finding of diminished steady-state IL-1 $\beta$  mRNA levels under these conditions may have been related to either decreased gene transcription or accelerated mRNA degradation. The observation that *L. donovani* inhibited IL-1 syn-

thesis at different levels along the induction pathway, according to the secondary stimulus involved (i.e., *S. aureus* vs. LPS) is consistent with previous studies in which stimulus-specific regulation of IL-1 production by mononuclear phagocytes was shown. For instance, Kunkel et al. (31) found IL-1 production by murine macrophages to be differentially regulated according to whether the inducing stimulus used was phagocytic or soluble. Furthermore, Fenton and co-workers (32) demonstrated that independent mechanisms regulated phorbol ester vs. LPS induction of IL-1 production by THP-1 cells, by human monocytes and by the HL-60 myelocytic cell line.

Inhibition of monocyte IL-1 production by *Leishmania* both at the level of mRNA accumulation (in response to *S. aureus*) as well as posttranscriptionally (in response to LPS or *S. aureus*), is also consistent with data demonstrating that IL-1 expression is subject to regulatory control at each of these levels. Thus, glucocorticoids have been shown to suppress IL-1 $\beta$  gene transcription and mRNA accumulation in cells of the promonocyte cell line U937 (33, 34). Lew and co-workers also reported suppression of LPS-induced IL-1 $\alpha$  and IL-1 $\beta$  mRNA accumulation in adherent human monocytes treated with prednisolone (35), although Kern et al. noted only post-transcriptional suppression of IL-1 production in dexamethasone treated human monocytes in suspension culture (36). Furthermore, both glucocorticoids (33, 36) and elevated levels of prostaglandins (34) have been shown to downregulate IL-1 expression posttranscriptionally through a cAMP-dependent pathway (34, 37). In regard to the latter, we have previously shown that macrophages respond to infection with *L. donovani* with increased synthesis of prostaglandin E<sub>2</sub> (38) and such a mechanism could explain a predominantly posttranscriptional suppression of the IL-1 response to either LPS or *S. aureus* in *Leishmania*-infected cells. Attempts to demonstrate such a relationship by treating cells with cyclooxygenase inhibitors such as indomethacin or sodium meclofenamate prior to and during *Leishmania* infection, did not result in the restoration the IL-1 response to LPS (data not shown). A negative result from such an experiment does not, however, provide definitive evidence to exclude a role for prostaglandins. Thus, as has been shown by us (38) and by others (39, 40) these putative cyclooxygenase inhibitors lack specificity in that they also inhibit the metabolism of arachidonic acid via the lipoxigenase pathway. This consideration is of particular importance since evidence has been presented to indicate that lipoxigenase products of arachidonic acid promote monocyte IL-1 synthesis (41, 42). The failure of putatively specific cyclooxygenase inhibitors to restore the IL-1 response to LPS in *Leishmania*-preinfected cells could thus be related to countervailing effects of inhibitors on these dual pathways of arachidonic acid oxygenation.

As was the case for IL-1, the results of the present study furthermore indicate that infection of human monocytes with *L. donovani* did not result in increased TNF- $\alpha$  activity in monocyte supernatants. This result may be interpreted to indicate that *Leishmania* did not induce cytokine synthesis, since > 90% of TNF- $\alpha$  produced by fresh monocytes is found extracellularly (16). This interpretation is supported by the finding that TNF- $\alpha$  mRNA accumulation was not induced in monocytes in response to *Leishmania* alone (Fig. 5).

These findings demonstrate, therefore, that neither IL-1 nor TNF- $\alpha$  are produced by human monocytes in response to *Leishmania*. Of particular interest, however, was the observa-



tion that these two cytokines were not coordinately regulated during infection with *Leishmania*. Thus, in response to secondary stimuli the production of IL-1 was found to be inhibited in leishmania infected cells, but the production of TNF- $\alpha$  was unaffected. This selective inhibitory effect of *Leishmania* on the production of these two cytokines is consistent with the findings of Burchett et al., indicating that the synthesis of IL-1 and TNF- $\alpha$  in human monocytes are not coordinately regulated (16).

The finding that human monocytes were unresponsive to *Leishmania* with respect to cytokine production, and that infection inhibited IL-1 induction in response to secondary stimuli, prompted examination of whether these events could be modified by IFN- $\gamma$ . This approach was based upon data demonstrating the capacity of this lymphokine to upregulate IL-1 production by both freshly isolated human monocytes and by in vitro monocyte-derived macrophages (16–19). Treatment of cells with IFN- $\gamma$  before infection, primed cells to respond to *L. donovani* by producing both IL-1 ( $n = 6$  out of 9 experiments) and TNF- $\alpha$  ( $n = 3$  out of 5 experiments). Compared to cells that were not treated with lymphokine, the priming effect of IFN- $\gamma$  was greater (in absolute, but not relative terms) for monocyte production of TNF- $\alpha$  (in response to *Leishmania*) than it was for the synthesis of IL-1 (compare Fig. 8 and Table IV). This result is in agreement with previous results (16) indicating a quantitatively greater priming effect of IFN- $\gamma$  on monocyte production of TNF- $\alpha$  in comparison to IL-1.

In addition to converting cells from a nonresponsive state to a responsive one, with respect to cytokine production upon exposure to *Leishmania*, IFN- $\gamma$  was also able to abrogate parasite-induced inhibition of the IL-1 response to a second stimulus (Fig. 7). Both in the case of priming for cytokine production (Fig. 8) and also in preventing inhibition of the IL-1 response (Fig. 7), the efficacy of lymphokine treatment was time dependent. Treatment with IFN- $\gamma$  before exposure to *Leishmania* was required for maximal responses. When lymphokine treatment was initiated as little as 2 h after leishmania infection efficacy was lost.

Although the exact mechanism(s) whereby IFN- $\gamma$  modulated monocyte IL-1 and TNF- $\alpha$  responses to *Leishmania* are as yet unknown, this lymphokine has been shown to increase the duration of transcription of the genes encoding these cytokines when cells were activated by LPS (16). Enhancement by IFN- $\gamma$  of cytokine mRNA stabilities were also described (16). In addition, priming of cells by IFN- $\gamma$  for increased IL-1 responses to various stimuli may be related to modulation of monocyte arachidonic acid metabolism by this lymphokine. Prostaglandins of the E series inhibit monocyte IL-1 production (31, 37) and IFN- $\gamma$  has been shown to downregulate monocyte PGE<sub>2</sub> synthesis in response to a variety of agonists (43–46). Modulation by IFN- $\gamma$  of monocyte PGE<sub>2</sub> production in response to *Leishmania*, therefore, could potentially explain its capacity to upregulate cytokine production during in vitro infection.

Data from both the present and from previous experiments (25) clearly show that the direct interaction of *L. donovani* with mononuclear phagocytes does not result in the production of IL-1. In addition, here we present evidence that TNF- $\alpha$  is also not produced under these conditions. Considering that IL-1 and TNF- $\alpha$  represent two of the three (interferon- $\alpha$  being the third) currently recognized endogenous pyrogens (47),

these data must be viewed in light of the fact that fever is nearly a constant feature in patients with visceral leishmaniasis (13, 14). At least two explanations may account for this apparent paradox. First, patients with visceral leishmaniasis have been found to have circulating immune complexes (48, 49) and the latter have been shown to induce monocyte IL-1 production (29, 50). Secondly, it has recently been reported (51) that splenic macrophages obtained from Syrian hamsters infected with *L. donovani*, when cultured in vitro, produce increased amounts of IL-1 and TNF- $\alpha$ . In light of the findings of the present study, it is reasonable to postulate that the production of IFN- $\gamma$  locally within the spleen may prime tissue macrophages to produce TNF- $\alpha$  or IL-1 or both in response to *Leishmania*.

Previously, we reported that *L. donovani* inhibited the accumulation of MHC class II mRNA in infected macrophages in response to IFN- $\gamma$  (52). Recent data indicates that this effect is related to decreased transcription of MHC class II genes (P. Kwan, W. R. McMaster, W. Ng, and N. Reiner, manuscript in preparation). These observations, together with the finding of selective, post-transcriptional inhibition by *Leishmania* of stimulus-induced IL-1 production, raise questions regarding the effects of intracellular parasitism on mRNA translation, the stabilities of translated proteins and the integrity of signal transduction mechanisms in mononuclear phagocytes. Studies which are now underway are directed at examining these questions including defects in intracellular signalling which may contribute to abnormal responses observed in infected cells.

When considered in the context of accruing data, the findings of the present study may be of fundamental importance to the immunobiology of leishmania infections. Thus, based upon the ability of IFN- $\gamma$  to promote mononuclear phagocyte killing of *Leishmania* and a variety of other intracellular pathogens, clinical trials of immunotherapy with recombinant IFN- $\gamma$  in human visceral leishmaniasis were recently undertaken. Results of these studies indicated that this lymphokine was of therapeutic benefit in this disease (20). The mechanism accounting for the efficacy of IFN- $\gamma$  in this setting may have been related to the direct induction of monocyte killing of *Leishmania*. On the other hand, the findings of the present study, that IFN- $\gamma$  primes monocytes to produce both TNF- $\alpha$  and IL-1 in response to *Leishmania*, suggest a potential alternative mechanism by which IFN- $\gamma$  may mediate its therapeutic effect. Thus, both IL-1 and TNF- $\alpha$  have been shown to mediate antimicrobial effects against intracellular pathogens (3, 9–12). Moreover, and of direct relevance to the results of the present study, are the recent findings of Titus and co-workers that demonstrated a protective role for TNF- $\alpha$  in experimental leishmaniasis (15). This suggests the possibility that priming by IFN- $\gamma$  for monocyte TNF- $\alpha$  production (and perhaps IL-1) in response to *Leishmania* is a potential mechanism by which IFN- $\gamma$  mediates its therapeutic effect in vivo. Although direct evidence that IL-1 plays a role in the pathogenesis of leishmania infections has not yet been presented, it is reasonable to consider this a likely possibility given the considerable extent to which the biological activities of IL-1 and TNF overlap (4–8). Furthermore, the ability of IFN- $\gamma$  to promote monocyte IL-1 production in response to *Leishmania* may have other indirect effects on the immune response. Thus, numerous investigators have demonstrated cellular immune defects and deficiencies of lymphokine production in visceral

leishmaniasis (21, 53–55). The precise relationship of these immune deficiencies to inhibition of IL-1 production (which plays a central role in the evolution of a cellular immune response) by *Leishmania* remains to be defined. Nevertheless, the ability of mononuclear phagocytes primed in vivo with IFN- $\gamma$  to respond to *Leishmania* by producing IL-1 could potentially reverse some of these immune defects. Such an effect would favor the evolution of a protective, antileishmanial cell-mediated immune response, which is critical to ultimate cure (13, 14).

## Acknowledgments

We thank Drs. Steven Gillis and Kenneth H. Grabstein of Immunex Corp., Seattle, WA, and Drs. H. Michael Shepard, Patrick W. Gray, and Dianne Pennica of Genentech Inc., South San Francisco, CA, for providing reagents and probes. We are also grateful to Dr. Noel Buskard, Ms. June Humphreys, and the staff of the British Columbia and Yukon Division of the Canadian Red Cross for providing cells.

This work was supported by grants MA-8633 and MT-7399 from the Medical Research Council of Canada, grants 47(87-1) and 125(87-2) from the British Columbia Health Care Research Foundation, and by grants HD-18184, AI-00658 and HD-07233 from the National Institutes of Health. Dr. Reiner is the recipient of a Research Scholarship Award from the British Columbia Health Care Research Foundation.

## References

1. Unanue, E. R., and P. M. Allen. 1987. The basis for the immunoregulatory role of macrophages and other accessory cells. *Science (Wash. DC)*. 236:551–557.
2. Nathan, C. F. 1987. Secretory products of macrophages. *J. Clin. Invest.* 79:319–326.
3. Murray, H. W. 1988. Interferon- $\gamma$ , the activated macrophage, and host defense against microbial challenge. *Ann. Intern. Med.* 108:595–608.
4. Dinarello, C. A. 1984. Interleukin-1. *Rev. Infect. Dis.* 6:51–95.
5. Durum, S. K., J. A. Schmidt, and J. J. Oppenheim. 1985. Interleukin 1: an immunological perspective. *Annu. Rev. Immunol.* 3:263–87.
6. Oppenheim, J. J., E. J. Kovacs, K. Matsushima, and S. K. Durum. 1986. There is more than one interleukin 1. *Immunol. Today*. 7:45–56.
7. Dinarello, C. A. 1988. Biology of interleukin 1. *FASEB (Fed. Am. Soc. Exp. Biol.) J.* 2:108–115.
8. Beutler, B., and A. Cerami. 1986. Cachectin and tumour necrosis factor as two sides of the same biological coin. *Nature (Lond.)*. 320:583–588.
9. De Titto, E. H., J. R. Catterall, and J. S. Remington. 1986. Activity of recombinant tumor necrosis factor on *Toxoplasma gondii* and *Trypanosoma cruzi*. *J. Immunol.* 137:1342–1345.
10. Czuprynski, C. J., J. F. Brown, K. M. Young, A. J. Cooley, and R. S. Kurtz. 1988. Effects of murine recombinant interleukin 1 $\alpha$  on the host response to bacterial infection. *J. Immunol.* 140:962–968.
11. Bermudez, L. E. M., and L. S. Young. 1988. Tumor necrosis factor alone or in combination with IL-2, but not interferon- $\gamma$ , is associated with macrophage killing of *Mycobacterium avium* complex. *J. Immunol.* 140:3006–3013.
12. Ozaki, Y., T. Ohashi, A. Minami, and S.-I. Nakamura. 1987. Enhanced resistance of mice to bacterial infection induced by recombinant human IL 1- $\alpha$ . *Infect. Immun.* 55:1436–1440.
13. Wyler, D. J., and P. D. Marsden. 1983. Leishmaniasis. In *Tropical and Geographical Medicine*. K. S. Warren, A. A. F. Mahmoud, editors. McGraw-Hill Book Co., Inc. New York. 270–280.
14. Pearson, R. D., D. A. Wheeler, L. H. Harrison, and H. D. Kay. 1984. The immunobiology of leishmaniasis. *Rev. Infect. Dis.* 5:907–927.
15. Titus, R. G., B. Sherry, and A. Cerami. 1989. Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. *J. Exp. Med.* 170:2097–2104.
16. Burchett, S. K., W. M. Weaver, J. A. Westall, A. Larsen, S. Kronheim, and C. B. Wilson. 1988. Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. *J. Immunol.* 140:3473–3481.
17. Gerrard, T. L., J. P. Siegel, D. R. Dyer, and K. C. Zoon. 1987. Differential effects of interferon- $\alpha$  and interferon- $\gamma$  on interleukin 1 secretion by monocytes. *J. Immunol.* 138:2535–2540.
18. Arenzana-Seisdedos, F., J. L. Virelizier, and W. Fiers. 1985. Interferons as macrophage-activating factors. III. Preferential effects of interferon- $\gamma$  on the interleukin 1 secretory potential of fresh or aged human monocytes. *J. Immunol.* 134:2444–2448.
19. Haq, A. U., J. J. Rinehart, and R. D. Maca. 1985. The effect of gamma interferon on IL-1 secretion of in vitro differentiated human macrophages. *J. Leukocyte Biol.* 38:735–746.
20. Badaro, R., E. Falcoff, F. S. Badaro, E. M. Carvalho, D. Pedral-Sampaio, A. Barral, J. S. Carvalho, M. Barral-Netto, M. Brandley, L. Silva, J. C. Bina, R. Teixeira, R. Falcoff, H. Rocha, J. L. Ho, and W. D. Johnson. 1990. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. *N. Engl. J. Med.* 322:16–21.
21. Reiner, N. E. 1982. Host-parasite relationship in murine leishmaniasis: pathophysiological and immunological changes. *Infect. Immun.* 38:1223–1230.
22. Gray, P. W., D. Glaister, E. Chen, D. V. Goeddel, and D. Pennica. 1986. Two interleukin 1 genes in the mouse: cloning and expression of the cDNA for murine IL 1 $\beta$ . *J. Immunol.* 137:3644–3648.
23. Pennica, D., G. E. Nedwin, J. S. Hayflick, P. H. Seeburg, R. Derynck, M. A. Palladino, W. J. Kohr, B. B. Aggarwal, and D. V. Goeddel. 1984. Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin. *Nature (Lond.)*. 312:724–729.
24. Kaye, J. S., S. Gillis, S. B. Mizel, E. M. Shevach, T. R. Malek, C. A. Dinarello, L. B. Lachmann, and C. A. Janeway. 1984. Growth of a cloned helper T-cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. *J. Immunol.* 133:1339–1345.
25. Reiner, N. E. 1987. Parasite accessory cell interactions in murine leishmaniasis 1. Evasion and stimulus-dependent suppression of the macrophage interleukin 1 response by *Leishmania donovani*. *J. Immunol.* 138:1919–1925.
26. Chirgwin, J. M., A. E. Przybyla, R. J. McDonald, and W. J. Rutter. 1979. Isolation of biologically active ribonucleic acid from sources enriched in ribonucleases. *Biochemistry*. 18:5294–5299.
27. Lerach, H., D. Diamond, J. M. Wozney, and H. Boedtker. 1977. RNA molecular weight determinations by gel electrophoresis under denaturing conditions: a critical re-examination. *Biochemistry*. 16:4743–4751.
28. Feinberg, A. P., and B. Vogelstein. 1983. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. *Anal. Biochem.* 132:613.
29. Crawford, G. D., D. J. Wyler, and C. A. Dinarello. 1985. Parasite-macrophage interactions in human leishmaniasis: production of interleukin-1 in vitro. *J. Infect. Dis.* 152:315–322.
30. Cillari, E., M. Dieli, E. Maltese, S. Milano, A. Salerno, and F. Y. Liew. 1989. Enhancement of macrophage IL-1 production by *Leishmania major* infection in vitro and its inhibition by IFN- $\gamma$ . *J. Immunol.* 143:2001–2005.
31. Kunkel, S. L., S. W. Chensue, and S. H. Phan. 1986. Prostaglandins as endogenous mediators of interleukin 1 production. *J. Immunol.* 136:186–192.
32. Fenton, M. J., M. W. Vermeulen, B. D. Clark, A. C. Webb, and P. E. Auron. Human pro-IL-1 $\beta$  gene expression in monocytic cells is regulated by two distinct pathways. *J. Immunol.* 140:2267–2273.

33. Lee, S. L., A. P. Tsou, H. Chan, J. Thomas, K. Petrie, E. M. Eugui, and A. C. Allison. 1988. Glucocorticoids selectively inhibit the transcription of the interleukin 1 $\beta$  gene and decrease the stability of interleukin 1 $\beta$  mRNA. *Proc. Natl. Acad. Sci. USA*. 85:1204-1208.
34. Knudsen, P. J., C. A. Dinarello, and T. B. Strom. 1987. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. *J. Immunol.* 139:4129-4134.
35. Lew, L., J. J. Oppenheim, and K. Matsushima. 1988. Analysis of the suppression of IL-1 $\alpha$  and IL-1 $\beta$  production in human peripheral blood mononuclear adherent cells by a glucocorticoid hormone. *J. Immunol.* 140:1895-1902.
36. Kern, J. A., R. L. Lamb, J. C. Reed, R. P. Daniele, and P. C. Nowell. 1988. Dexamethasone inhibition of interleukin 1 beta production by human monocytes. *J. Clin. Invest.* 81:237-244.
37. Knudsen, P. J., C. A. Dinarello, and T. B. Strom. 1986. Prostaglandins post-transcriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. *J. Immunol.* 137:3189-3194.
38. Reiner, N. E., and C. J. Malemud. 1985. Arachidonic acid metabolism by *Leishmania donovani* infected murine peritoneal macrophages: in vitro evidence for parasite-induced alterations in cyclooxygenase and lipoxygenase pathways. *J. Immunol.* 134:556-563.
39. Paaanen, H., J. Mannisto, and P. Utoila. 1982. Aspirin inhibits arachidonic acid metabolism via lipoxygenase and cyclooxygenase in hamster isolated lungs. *Prostaglandins*. 23:731-.
40. Myers, R. F., and M. I. Siegel. 1983. Differential effects of anti-inflammatory drugs on lipoxygenase and cyclooxygenase activities of neutrophils from a reverse passive arthus reaction. *Biochem. Biophys. Res. Commun.* 112:586-.
41. Dinarello, C. A., I. Bishai, L. J. Rosenwasser, and F. Coceani. 1984. The influence of lipoxygenase inhibitors on the in vitro production of human leukocytic pyrogen and lymphocyte activating factor (interleukin-1). *J. Immunopharmacol.* 6:43-50.
42. Rola-Pleszczynski, M., and I. Lemaire. 1985. Leukotrienes augment interleukin 1 production by human monocytes. *J. Immunol.* 135:3958-3961.
43. Russell, S. W., and J. L. Pace. 1984.  $\gamma$ -interferon interferes with the negative regulation of macrophage activation by prostaglandin E. *Mol. Immunol.* 21:249-254.
44. Boraschi, D., S. Censini, and A. Tagliabue. 1984. Interferon- $\gamma$  reduces macrophage-suppressive activity by inhibiting prostaglandin E<sub>2</sub> release and inducing interleukin 1 production. *J. Immunol.* 133:764-767.
45. Boraschi, D., S. Censini, M. Bartalini, and A. Tagliabue. 1985. Regulation of arachidonic acid metabolism in macrophages by immune and nonimmune interferons. *J. Immunol.* 135:502-505.
46. Browning, J. L., and A. Ribolini. 1987. Interferon blocks interleukin 1-induced prostaglandin release from human peripheral monocytes. *J. Immunol.* 138:2857-2863.
47. Dinarello, C. A., J. G. Cannon, S. M. Wolff, H. A. Bernheim, B. Beutler, A. Cerami, I. S. Figari, M. A. Palladino, Jr., and J. V. O'Connor. 1986. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. *J. Exp. Med.* 163:1433-1450.
48. Carvalho, E. M., B. S. Andrews, R. Martinelli, M. Dutra, and M. Rusha. 1983. Circulating immune complexes and rheumatoid factor in schistosomiasis and visceral leishmaniasis. *Am. J. Trop. Med. Hyg.* 32:61-68.
49. Pearson, R. D., J. E. Alencar, R. Romito, T. G. Naidu, A. C. Young, and J. S. Davis. 1983. IV. Circulating immune complexes and rheumatoid factors in visceral leishmaniasis. *J. Infect. Dis.* 147:1102.
50. Arend, W. P., F. G. Joslin, and R. J. Massoni. 1985. Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. *J. Immunol.* 134:3868-3875.
51. Pearson, R. D., T. Evans, D. Smith, D. Wiedel, K. Mason, and J. Castracane. 1988. Wasting and macrophage production of interleukin 1 and tumor necrosis factor/cachectin in visceral leishmaniasis. *Clin. Res.* 36:466A. (Abstr.)
52. Reiner, N. E., W. Ng, T. Ma, and W. R. McMaster. 1988. Kinetics of IFN- $\gamma$  binding and MHC class II mRNA levels in leishmania-infected macrophages. *Proc. Natl. Acad. Sci. USA*. 85:4330-4334.
53. Murray, H. W., H. Masur, and J. S. Keithly. 1982. Cell-mediated immune response in experimental visceral leishmaniasis. I. Correlation between resistance to *Leishmania donovani* and lymphokine-generating capacity. *J. Immunol.* 131:1487-1491.
54. Reiner, N. E., and J. H. Finke. 1983. Interleukin 2 deficiency in murine leishmaniasis donovani and its relationship to depressed spleen cell responses to phytohemagglutinin. *J. Immunol.* 131:1487-1491.
55. Carvalho, E. M., R. Badaro, S. G. Reed, T. C. Jones, and W. D. Johnson, Jr. 1985. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. *J. Clin. Invest.* 76:2066-2069.